ERK 1/2 signaling pathway is involved in nicotine-mediated neuroprotection in spinal cord neurons
✍ Scribed by Michal Toborek; Kwang Won Son; Anna Pudelko; Kelley King-Pospisil; Edward Wylegala; Andrzej Malecki
- Book ID
- 102304589
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 411 KB
- Volume
- 100
- Category
- Article
- ISSN
- 0730-2312
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Evidence indicates that agonists of neuronal nicotinic receptors (nAChRs), including nicotine, can induce neuroprotective and anti‐apoptotic effects in the CNS. To study these mechanisms, the present study focused on nicotine‐mediated modulation of the extracellular regulated kinase 1 and 2 (ERK1/2) pathway in cultured spinal cord neurons. Exposure to nicotine (0.1–10 µM) for as short as 1 min markedly upregulated levels of phosphorylated ERK1/2 (pERK1/2) and increased total ERK1/2 activity. Inhibition studies with mecamylamine and α‐bungarotoxin revealed that these effects were mediated by the α7 nicotinic receptor. In addition, pre‐exposure to U0126, a specific inhibitor of the ERK1/2 signaling, prevented nicotine‐mediated anti‐apoptotic effects. To indicate if treatment with nicotine also can activate ERK1/2 in vivo, a moderate spinal cord injury (SCI) was induced in rats using a weight‐drop device and nicotine was injected 2 h post‐trauma. Consistent with in vitro data, nicotine increased levels of pERK1/2 in this animal model of spinal cord trauma. Results of the present study indicate that the ERK1/2 pathway is involved in anti‐apoptotic effects of nicotine in spinal cord neurons and may be involved in therapeutic effects of nicotine in spinal cord trauma. J. Cell. Biochem. 100: 279–292, 2007. © 2006 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract Macrophages are critically involved in the pathogenesis of genetically caused demyelination, as it occurs in inherited demyelinating neuropathies. On the basis of the observation that upregulation of the Schwann cell‐derived chemokine MCP‐1 (CCL2) is a pathologically relevant mechanism